期刊文献+

局限性前列腺癌调强适形放疗联合间歇性内分泌治疗的疗效评价 被引量:6

The therapeutic evaluation of intensity modulated radiation therapy combined with intermittent hormonal therapy for localized prostate cancer
下载PDF
导出
摘要 目的探讨调强适形放射治疗(intensity modulated radiation therapy,IMRT)联合间歇性内分泌治疗(intermittent hormonal therapy,IHT)方法治疗局限性前列腺癌的疗效评价。方法将72例同期局限性前列腺癌患者随机分为两组,分别进行调强适形放射治疗联合间歇性内分泌治疗(37例)和单纯调强适形放射治疗(35例),分析比较两组患者的临床症状缓解率、前列腺体积变化、血清前列腺特异性抗原(PSA)值改变、肿瘤控制率、放疗不良反应发生率及生存率。结果随访5~118个月,平均56个月,联合治疗组与单纯治疗组比较,临床症状缓解率、前列腺体积差值、血清PSA〈0.2μg/L者所占比例及治疗后1年、3年、5年和8年的PSA无进展生存率差异均有统计学意义(P〈0.05);治疗后1年、3年两组均无死亡病例,差异无统计学意义,治疗后5年、8年的生存率和早期放疗不良反应发生率两组间差异均有统计学意义(P〈0.05)。结论调强适形放射治疗联合间歇性内分泌治疗方法治疗局限性前列腺癌可明显缓解患者的临床症状,降低血清PSA水平,提高疾病控制率及生存率,降低放疗早期不良反应发生率,疗效优于单纯调强适形放射治疗,是一种安全、有效的治疗措施。 Objective To investigate the clinical therapeutic effect of intensity modulated radiation therapy (IMRT) combined with intermittent hormonal therapy (IHT) for localized prostate cancer. Method 72 patients with localized prostate cancer of same stage were randomized into two groups, receiving IMRT + IHT ( 37 cases) or simple IMRT (35 cases) , and the clinical response rate, prostate volume, serum PSA, tumor control rate, adverse events incidence and survival rate of the two groups were compared. Result All patients were followed up for 5 to 118 months and mean time was 56 months. The clinical response rate, difference of prostate volume, proportion of patients with serum PSA〈0. 2 txg/ L, and the PSA-free survival rate in 1, 3, 5, and 8 years after treatment showed statistically significant difference between the two groups ( P〈0. 05) ; There was no death in 1 and 3 years after treatment in both groups, which was not statistically different, while the survival rate of the two groups in 5 and 8 years post treatment showed statistically significant difference (P〈0. 05). Conclusion IMRT + IHT effectively relieve clinical symptoms of patients, and lower serum PSA level, improve tumor control rate and survival rate as well as reduce adverse events, which is a safe and effective remedy with better therapeutic effect than simple IMRT.
出处 《癌症进展》 2014年第1期9-15,共7页 Oncology Progress
关键词 局限性前列腺癌 间歇性内分泌治疗 调强适形放射治疗 localized prostate cancer intermittent hormonal therapy intensity modulated radiation therapy
  • 相关文献

参考文献11

  • 1张晓智,黄珊.要重视放射治疗在前列腺癌治疗中的作用[J].现代泌尿外科杂志,2011,16(3):187-191. 被引量:11
  • 2Bagshaw A, Cox RS, Ramback JE. Radiation therapy for localized prostate cancer. Justification by long-term follow- up [J]. Urol Clin North Am, 1990, 17 (4) : 787-802.
  • 3张国辉,王金萍,关亚伟,艾星,张水文,郑清友.局限性前列腺癌间歇性内分泌治疗的临床观察[J].现代泌尿外科杂志,2011,16(2):123-125. 被引量:13
  • 4Zelefsky MJ, Chan H, Hunt M, et al. Long-term out- come of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer [ J ]. J Urol, 2006, 176 (4 Pt 1) : 1415-1419.
  • 5Aizer AA, Yu JB, Colberg JW, et al. Radical prostatec- tomy vs. intensity-modulated radiation therapy in the man- agement of localized prostate adenocarcinoma [ J ]. Ra- diother Oncol, 2009, 93 (2) : 185-191.
  • 6Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer [ J ]. Urol Clin North Am, 1975, 2 (1) : 105-124.
  • 7Bagshaw MA, Pistenma DA, Ray GR, et al. Evaluation of extended-field radiotherapy for prostatic neoplasm : 1976progress report [J]. Cancer Treat ReP, 1977, 61 (2) : 297-306.
  • 8Ravery V, Boceon-Gibod LA, Dauge-Geffroy MC, et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detect- able PSA after radical prostateetomy [ J ]. Urology, 1994, 44 (3) :371-376.
  • 9蒋跃庆,王忠,任晓敏,姚海军,张霖.三维适形放疗联合内分泌治疗前列腺癌[J].中国男科学杂志,2010,24(8):30-32. 被引量:7
  • 10Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [ J ]. N Engl J Med, 1997, 337 (5) :295-300.

二级参考文献47

  • 1吴永安.局限性前列腺癌的根治性放射治疗[J].中国医师进修杂志(外科版),2006,29(2):15-17. 被引量:2
  • 2Bagshaw MA, Cox RS, Ramback JE. Radiation therapy for localized prostate cancer. Justification by long-time follow-up. Urol Clin North Am 1990; 17(4): 787-802.
  • 3Mettlin C J, Murphy GP, Cunningham MP, et al. The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment. Cancer 1997; 80(7): 1261-1266.
  • 4Richard GS, Jamie AC, Simon JH, et al. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009; 104(11): 1631- 1636.
  • 5Zelefsky M J, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41(3): 491-500.
  • 6Hanks GE, Hanlon AL, Schultheiss TE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998; 41(3): 501-510.
  • 7RIES LAG, HARKINS D, KRAPCHOM, et al. SEER cancer statistics review, 1975-2003 [DB/OL]. National cancer institute 2006E2011-01-303. http://seer, cancer, gov/csr/1975-2003.
  • 8JEMAL A, SIEGAEL R, WARD E, et al. Cancer statistics, 2009[J].CA Cancer J Clin, 2009, 59:225-249.
  • 9JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics 2007 [J].CA Cancer J Clin 2007 ; 57 : 43-66.
  • 10FERLAY J, BRAY F, PISANI P, et al. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5 [CP/DK]. version 2.0. Lyon, France: IARC Press, 2004', GLOBOCAN 2002.

共引文献22

同被引文献42

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部